BACKGROUND: The aim of this multicentric study was to identify human papillomavirus (HPV) type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia 2/3 (CIN2/3) in Italy. METHODS: Cases were sampled through the electronic databases at the pathology units of eight centers in six regions from central and southern Italy. HPV types were detected from paraffin-embedded tissue samples and cervical specimens through amplification of HPV DNA with GP5+/GP6+ primers, followed by genotyping with reverse line blot (RLB). Untyped HPV-positive samples were sequenced. HPV-negative samples underwent nested PCR, followed by either RLB or sequencing. Finally, the remaining HPV-negative samples were amplified with primers targeting the virus E6 to E7 regions. RESULTS: From 1,162 cases initially selected, 722 samples were further analyzed: 144 CIN2, 385 CIN3, 157 invasive squamous carcinomas, and 36 adenocarcinomas. Samples (6.9%) were HPV negative. The proportion of HPV16/18 was 60.8%, 76.6%, and 78.8% in CIN2, CIN3, and invasive cancers, respectively (P trend = 0.004). There was a significant decreasing trend of HPV16/18 with age in invasive cancers, going from 92% in women <35 years to 73% in women >55 years (P = 0.036). The proportion of coinfections was 16.8%, 15.5%, and 10.0% in CIN2, CIN3, and invasive cancers, respectively (P trend = 0.07). CONCLUSIONS: The proportion of invasive cancers caused by HPV16/18 decreases with age at diagnosis. IMPACT: The absolute risk of an invasive cancer due to non-HPV16/18 in women under 35 is extremely low. This finding might prompt us to rise the age at which public HPV screening for vaccinated women should start. (c)2010 AACR.
BACKGROUND: The aim of this multicentric study was to identify human papillomavirus (HPV) type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia 2/3 (CIN2/3) in Italy. METHODS: Cases were sampled through the electronic databases at the pathology units of eight centers in six regions from central and southern Italy. HPV types were detected from paraffin-embedded tissue samples and cervical specimens through amplification of HPV DNA with GP5+/GP6+ primers, followed by genotyping with reverse line blot (RLB). Untyped HPV-positive samples were sequenced. HPV-negative samples underwent nested PCR, followed by either RLB or sequencing. Finally, the remaining HPV-negative samples were amplified with primers targeting the virus E6 to E7 regions. RESULTS: From 1,162 cases initially selected, 722 samples were further analyzed: 144 CIN2, 385 CIN3, 157 invasive squamous carcinomas, and 36 adenocarcinomas. Samples (6.9%) were HPV negative. The proportion of HPV16/18 was 60.8%, 76.6%, and 78.8% in CIN2, CIN3, and invasive cancers, respectively (P trend = 0.004). There was a significant decreasing trend of HPV16/18 with age in invasive cancers, going from 92% in women <35 years to 73% in women >55 years (P = 0.036). The proportion of coinfections was 16.8%, 15.5%, and 10.0% in CIN2, CIN3, and invasive cancers, respectively (P trend = 0.07). CONCLUSIONS: The proportion of invasive cancers caused by HPV16/18 decreases with age at diagnosis. IMPACT: The absolute risk of an invasive cancer due to non-HPV16/18 in women under 35 is extremely low. This finding might prompt us to rise the age at which public HPV screening for vaccinated women should start. (c)2010 AACR.
Authors: Anna Gillio-Tos; Laura De Marco; Francesca Maria Carozzi; Annarosa Del Mistro; Salvatore Girlando; Elena Burroni; Helena Frayle-Salamanca; Paolo Giorgi Rossi; Paola Pierotti; Guglielmo Ronco Journal: J Clin Microbiol Date: 2013-06-26 Impact factor: 5.948
Authors: Julia W Gargano; Rosane Nisenbaum; Daisy R Lee; Mack T Ruffin; Martin Steinau; Ira R Horowitz; Lisa C Flowers; Talaat S Tadros; George Birdsong; Elizabeth R Unger Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-10-25 Impact factor: 4.254
Authors: Mariska Bierkens; Saskia M Wilting; Wessel N van Wieringen; Mark A van de Wiel; Bauke Ylstra; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen Journal: BMC Cancer Date: 2012-01-24 Impact factor: 4.430
Authors: Paolo Giorgi Rossi; Francesco Chini; Simonetta Bisanzi; Elena Burroni; Giuseppe Carillo; Amedeo Lattanzi; Claudio Angeloni; Aurora Scalisi; Rosalba Macis; Maria T Pini; Paola Capparucci; Gabriella Guasticchi; Francesca M Carozzi Journal: Infect Agent Cancer Date: 2011-01-20 Impact factor: 2.965
Authors: Marta Elena Álvarez-Argüelles; Santiago Melón; Maria Luisa Junquera; Jose Antonio Boga; Laura Villa; Sonia Pérez-Castro; María de Oña Journal: PLoS One Date: 2013-01-23 Impact factor: 3.240
Authors: Paolo Giorgi Rossi; Mario Sideri; Francesca Maria Carozzi; Amina Vocaturo; Franco Maria Buonaguro; Maria Lina Tornesello; Elena Burroni; Luciano Mariani; Sara Boveri; Leandra Maria Zaffina; Francesco Chini Journal: Infect Agent Cancer Date: 2012-10-12 Impact factor: 2.965
Authors: David K Walmer; Paul S Eder; Laura Bell; Hiam Salim; Lori Kobayashi; Jackie Ndirangu; Nicole Tinfo; Philip E Castle Journal: PLoS One Date: 2013-10-03 Impact factor: 3.240